Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: Where we are now and where we are going

Nature Clinical Practice Urology

Volumn 4, Issue 7, 2007, Pages 379-386

  Sahai, Arun ^a   Khan, Mohammad S ^a   Gregson, Norman ^a   Smith, Kenneth ^a   Dasgupta, Prokar ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR RECEPTOR; NEUROKININ A; NITRIC OXIDE; PLACEBO; PURINE P2 RECEPTOR; SUBSTANCE P; TACHYKININ RECEPTOR; VANILLOID RECEPTOR; MUSCLE RELAXANT AGENT;

ACETYLCHOLINE RELEASE; BLADDER CONTRACTION; BLADDER DISEASE; BLADDER INNERVATION; CLINICAL TRIAL; CONSTIPATION; CYSTOMETRY; CYSTOSCOPY; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPOTHESIS; INHIBITION KINETICS; MALAISE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MUSCLE WEAKNESS; MYOFIBROSIS; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PARASYMPATHETIC NERVE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SYMPTOM; TREATMENT OUTCOME; URINARY URGENCY; URODYNAMICS; XEROSTOMIA; ANIMAL; CONTROLLED CLINICAL TRIAL; MALE; NEUROGENIC BLADDER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; BOTULINUM TOXIN TYPE A; HUMANS; MALE; NEUROMUSCULAR AGENTS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 34547786101     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0839     Document Type: Review

References (40)

1. Karsenty G et al. (2006) Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: A review of indications, techniques and results. Can J Urol 13 3027-3033
2. Chuang YC et al. (2006) The potential and promise of using botulinum toxin in the prostate gland. BJU Int 98: 28-32
3. Schurch B et al. (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174: 196-200
4. Popat R et al. (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174: 984-989
5. Finney SM et al. (2006) A double-blind, placebo controlled study investigating efficacy of botulinum toxin type A (Dysport) in MS related overactive bladder syndrome (OAB): Provisional 12-week clinical results [abstract]. BJU Int 97: 31-32
6. Ehren I et al. (2006) Treatment with botulinum toxin A in neurogenic bladder dysfunction - a randomised double-blind study with Dysport [abstract]. Eur Urol 5 (Suppl): 299
7. Sahai A et al. Efficacy of botulinum toxin-A in treating idiopathic detrusor overactivity: Results from a single center, randomised, double blind, placebo controlled trial. J Urol (in press)
8. Ghei M et al. (2005) Effects of botulinum toxin B on refractory detrusor overactivity: A randomized, double-blind, placebo controlled, crossover trial. J Urol 174: 1873-1877
9. Odergren T et al. (1998) A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64: 6-12
10. Schmid DM et al. (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176: 177-185
11. Sahai A et al. (2006) Urodynamic assessment of poor responders following intra-detrusor injections of botulinum toxin A for overactive bladder [abstract]. J Endourol 20 (Suppl 1): A60
12. Patki PS et al. (2006) Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 98: 77-82
13. Ruffion A et al. (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97: 1030-1034
14. Wyndaele JJ and Van Dromme SA (2002) Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40: 599-600
15. Grosse J et al. (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47: 653-659
16. Comperat E et al. (2006) Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50: 1058-1064
17. Haferkamp A et al. (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 46: 784-791
18. Dong M et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596
19. Schurch B et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692-697
20. Sahai A et al. (2005) Botulinum toxin for the treatment of lower urinary tract symptoms: A review. Neurourol Urodyn 24: 2-12
21. Apostolidis A et al. (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49: 644-650
22. Smet PJ et al. (1997) Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 77: 37-49
23. Khera M et al. (2004) Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 45: 987-993
24. Rapp DE et al. (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175: 1138-1142
25. Chuang YC et al. (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 72: 1529-1532
26. Atiemo H et al. (2005) Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 65: 622-626
27. Apostolidis A et al. (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174 977-982
28. Welch MJ et al. (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38: 245-258
29. Purkiss JR et al. (1998) A method for the measurement of [3H]-glutamate release from cultured dorsal root ganglion neurons. Biochem Soc Trans 26: S108
30. Cui M et al. (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107: 125-133
31. Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26: 785-793
32. Jankovic J and Schwartz K (1990) Botulinum toxin injections for cervical dystonia. Neurology 40: 277-280
33. Sahai A et al. (2006) Techniques for the intradetrusor administration of botulinum toxin. BJU Int 97: 675-678
34. Harper M et al. (2003) A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92: 325-326
35. Smith CP and Chancellor MB (2005) Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 19: 880-882
36. Smith CP et al. (2005) Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65: 37-41
37. Schulte-Baukloh H and Knispel HH (2005) A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 95: 454
38. Karsenty G et al. (2005) Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI) - a prospective randomized study to compare 30 vs 10 injection sites [abstract]. Neurourol Urodyn 24: 5-6
39. Boy S et al. (2006) Botulinum toxin injections into the bladder wall - a morphological evaluation of the injection technique using magnetic resonance imaging [abstract]. Eur Urol 5 (Suppl): 299
40. Khera M et al. (2005) In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 66: 208-212